---
title: "EuroEyes to Make Very Substantial Acquisition of FYEO Europe and Resume Trading"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/277066551.md"
description: "EuroEyes International Eye Clinic Limited (HK:1846) has announced a substantial acquisition of FYEO Europe B.V. through its Netherlands subsidiary, pending shareholder approval. The deal, exceeding 100% in applicable percentage ratio, requires reporting and circulars under Hong Kong listing rules. A detailed circular will be sent to shareholders by June 30, 2026, with an extraordinary general meeting expected by July 24, 2026. Trading of EuroEyes shares, halted on February 23, 2026, will resume on February 27, 2026, subject to conditions. The current analyst rating for EuroEyes stock is a Hold with a price target of HK$3.00."
datetime: "2026-02-26T15:10:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277066551.md)
  - [en](https://longbridge.com/en/news/277066551.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277066551.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/277066551.md) | [繁體中文](https://longbridge.com/zh-HK/news/277066551.md)


# EuroEyes to Make Very Substantial Acquisition of FYEO Europe and Resume Trading

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

EuroEyes International Eye Clinic Limited ( (HK:1846) ) has issued an update.

EuroEyes International Eye Clinic Limited has agreed, via its Netherlands subsidiary, to acquire the entire issued share capital of FYEO Europe B.V. from a group of independent vendors, in a transaction classified under Hong Kong listing rules as a very substantial acquisition. The deal, which will be settled based on an equity consideration adjusted for locked-box compensation and leakage, is expected to significantly enlarge the group once completed, pending shareholder approval at an extraordinary general meeting.

Because the highest applicable percentage ratio for the acquisition, alone or together with a related subscription, exceeds 100 percent, the transaction triggers reporting, circular and shareholder approval requirements under Chapter 14 of the listing rules. The company plans to dispatch a detailed circular, including pro forma financial information on the enlarged group, to shareholders by 30 June 2026, with the EGM expected on or before 24 July 2026.

The board has stated that, to its best knowledge, no existing shareholder has a material interest in the acquisition or the subscription, so no shareholder is currently required to abstain from voting on the relevant resolutions at the EGM. Trading in EuroEyes shares, which was halted on 23 February 2026 pending this announcement, is set to resume on 27 February 2026, though completion of the acquisition remains subject to satisfaction or waiver of conditions precedent, prompting a cautionary note to investors.

The most recent analyst rating on (HK:1846) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on EuroEyes International Eye Clinic Limited stock, see the HK:1846 Stock Forecast page.

**More about EuroEyes International Eye Clinic Limited**

EuroEyes International Eye Clinic Limited is a Hong Kong-listed ophthalmic services provider focused on corrective eye surgery and vision care. The group operates specialized clinics and related medical facilities in Europe and other markets, with growth driven by strategic acquisitions and expansion of its clinical network.

**Average Trading Volume:** 99,281

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$959.3M

### 相关股票

- [EUROEYES (01846.HK)](https://longbridge.com/zh-CN/quote/01846.HK.md)

## 相关资讯与研究

- [Euroeyes International Eye Clinic FY revenue HKD 796 million](https://longbridge.com/zh-CN/news/281223345.md)
- [Tata Motors' March 2026 sales rise 17%](https://longbridge.com/zh-CN/news/281325342.md)
- [Endeavour To Announce Its Q1 2026 Results On 30 April 2026 | EDVMF Stock News](https://longbridge.com/zh-CN/news/281490237.md)
- [Saab AB Approves Dividend for the Year 2025, Payable on 10 April 2026 and on 9 October 2026](https://longbridge.com/zh-CN/news/281402391.md)
- [BIC: Disclosure Of Trading In Own Shares For March 2026](https://longbridge.com/zh-CN/news/281651500.md)